Table 6 Pathway enrichment analysis of potential target genes in HN2092 for miRNAs responding to therapy in HNSCC patients (FDR < 0.05)
Pathway | Number of Proteins in Pathway | Proteins from Gene List | P-value | FDR | Genes |
|---|---|---|---|---|---|
ISG15 antiviral mechanism(R) | 71 | 4 | 0 | <1.000E-03 | NUP153,EIF4G2,NUP205,KPNA2 |
Viral carcinogenesis(K) | 206 | 4 | 0.0006 | 1.94E-02 | KAT2B,RBL2,CCND2,JUN |
HTLV-I infection(K) | 260 | 4 | 0.0013 | 3.58E-02 | KAT2B,MAD2L1,CCND2,JUN |
Aurora B signaling(N) | 40 | 3 | 0.0001 | 7.00E-03 | BIRC5,NPM1,PSMA3 |
Signaling events mediated by HDAC Class I(N) | 56 | 3 | 0.0002 | 1.17E-02 | NUP153,KAT2B,YY1 |
E2F transcription factor network(N) | 68 | 3 | 0.0003 | 1.34E-02 | KAT2B,RBL2,YY1 |
Validated targets of C-MYC transcriptional activation(N) | 72 | 3 | 0.0003 | 1.35E-02 | BIRC5,CCND2,NPM1 |
Mitotic Prophase(R) | 99 | 3 | 0.0009 | 2.79E-02 | NUP153,SET,NUP205 |
Nonsense-Mediated Decay(R) | 106 | 3 | 0.0010 | 3.07E-02 | SMG7,RPL30,RPL7 |
Cell cycle(K) | 124 | 3 | 0.0016 | 3.55E-02 | RBL2,MAD2L1,CCND2 |
Mitotic G1-G1/S phases(R) | 134 | 3 | 0.0020 | 3.66E-02 | RBL2,CCND2,PSMA3 |
Mitotic Metaphase and Anaphase(R) | 173 | 3 | 0.0042 | 4.77E-02 | BIRC5,MAD2L1,PSMA3 |